VIDEO: New treatments transform HCV management

Infectious Disease Week (IDWeek)
October 2-6, 2013
San Francisco, Ca

Provided by Healio

October 3, 2013

SAN FRANCISCO — Michael S. Saag, MD, of the University of Alabama at Birmingham, discusses the revolution in HCV treatments that have transformed the disease from a chronic infection with serious complications to a manageable and potentially curable condition.

Disclosures: Saag reports financial relationships with Bristol-Myers Squibb, Merck, Gilead, ViiV Healthcare, Abbvie, Boehringer Ingelheimand Pharmaceuticals and Janssen.

Source